Medicamentsen-ligne vous propose les traitements dont vous avez besoin afin de prendre soin de votre santé sexuelle. Avec plus de 6 ans d'expérience et plus de 90.000 clients francophones, nous étions la première clinique fournissant du
acheter kamagra original en France à vente en ligne et le premier vendeur en ligne de Kamagra dans le monde. Pourquoi prendre des risques si vous pouvez être sûr avec Medicamentsen-ligne - Le service auquel vous pouvez faire confiance.
Microsoft word - chantix _varenicline_ october 2006.doc
Chantix (varenicline) Tablets Review
Approved by FDA May 10, 2006 (Pfizer)
CHANTIX (varenicline) is a prescription NON-NICOTINIC smoking cessation treatment. It is a selective nicotinic receptor agonist indicated to aid in smoking cessation treatment in adults. Compared to previously available smoking cessation products (nicotine replacement therapy and bupropion sustained-release) it has a unique mechanism of action. It is a partial agonist selective for alpha-4, beta-2 nicotinic acetylcholine receptor subtypes. It binds with high affinity to these receptors, and its agonist action is thought to reduce the craving to smoke as well as the withdrawal symptoms from nicotine. By occupying the receptor sites, varenicline prevents binding of nicotine if the individual smokes while receiving treatment, thereby reducing the satisfaction associated with smoking.
Varenicline provides another option when considering available smoking cessation therapies.
Comparative studies with agents other than bupropion SR are not available. Efficacy and effectiveness
beyond 12 weeks or in populations other than those included in studies remains to be determined.
Varenicline, therefore, should be considered second line therapy in patients failing to quit using first line
alternatives of nicotine-replacement therapy (NRT) or bupropion SR smoking cessation therapy or having
a contraindication to those therapies. There are few contraindications or other restrictions and low
potential for drug interactions. Varenicline would not be added to hospital formularies at this time. In
an outpatient setting it offers a second line option when used as outlined in clinical trials.
Safety ─ (no long term data)
Sound Alike/Look Alike:*
CHANTIX has not been studied in patients younger than 18 years old.
Category Factor C
Chantix (varenicline) has not been studied in pregnant or nursing women and is therefore not recommended in these patients. No contraindications are included in the prescribing information. Varenicline is almost completely absorbed and minimally metabolized. Approximately 92% of a dose is excreted unchanged in the urine. Renal elimination is primarily through glomerular filtration along with active tubular secretion. Dosage adjustment in renal impairment is as follows: Clcr ≥30 mL/minute: No
adjustment required; Clcr <30 mL/minute. No dosage adjustment is required in hepatic impairment.
There are no clinically meaningful drug interactions observed for varenicline to date. It does not inhibit or
induce any of the following cytochrome P-450 enzymes: 1A2, 2A5, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and
3A4/5, or induce 1A2 or 3A4. Pharmacokinetic differences have not been noted due to age, race, gender
or smoking status. Mean age of study participants in the studies ranged from 42 to 45.4 for the various
randomized groupings. Successful cessation of smoking may alter pharmacokinetic properties of
other medications (eg, theophylline, warfarin, insulin).
Nausea was the most common side effect occurring in about 30% of patients in the studies.
Generally it was mild to moderate and for most people, but not all, it went away. In studies, more
than one in ten people who took varenicline had nausea, headache, trouble sleeping (18%), or
changes in dreams (13%). About 3% of patients discontinued treatment because of the nausea.
Studies were conducted in generally healthy smokers in clinical trials sponsored by Pfizer which provided
funding, study drug, placebo and monitoring. Two identically designed, 12 week studies with follow-up for
40 weeks were conducted (see below). The primary outcome was abstinence at weeks 9-12 and
secondarily continuous abstinence during the follow-up period. An additional study assessed the effects
of an additional 12 weeks of therapy. In all studies, patients received an educational booklet on smoking
cessation and received up to 10 minutes of counseling at each weekly
** Similarity of drug names involves confusion between look-alike and/or sound-alike brand names and/or trade names. This may be names may cause confusion when handwritten or communicated verbally.
Chantix (vareniclie) tablets page 2
Gonzales D. et al. JAMA 2006 296:47-55
Jorenby DE et al. JAMA. 2006 296:56-63
Varenicline Bupropion Placebo* Varenicline Bupropion Placebo*
* significance vs. varenicline
Exclusion criteria for studies included serious or unstable disease within 6 months, seizure risk, diabetes
mellitus requiring insulin or oral hypoglycemics medications, hepatic or renal impairment, clinically
significant cardiovascular disease within 6 months, uncontrolled hypertension, severe COPD, history of
cancer (except skin), history of clinically significant allergic reactions, major depressive disorder within the
past year requiring treatment, panic disorder, psychosis, bipolar disorder, eating disorders, alcohol or
drug abuse dependency within last year, use of tobacco products other than cigarettes, use of NRT,
clonidine, or nortriptyline with the month prior to enrollment, BMI <15 or >38, prior varenicline or
bupropion exposure, pregnant or nursing, investigational drug within 30 days, intention to donate blood or
blood products during the treatment phase, use of marijuana or other tobacco products, and clinically
significant abnormalities in screening lab values. In the Gonzales trial abstinence at 52 weeks shows
28.1% of the varencline group abstinent vs. 22.8 % of the bupropion SR group vs. placebo 14%.
Comparitive clinical trials between varenicline and other agents are not available, nor has the efficacy of it
in combination with other smoking cessation therapies been studied.
All patients receiving varenicline will have the opportunity to enroll in a free behavioral support program designed to help them address critical behavioral components of addiction and relapse.
Monthly Pricing: Gum at 9/day =, Patches (for 21mg, 14, or 7mg)
Dosing starts 1 week before target quit date. A course of treatment is 12 weeks.
Initial Dosing: Days 1-3: 0.5mg once daily, Days 4-7: 0.5mg twice daily
Packaging reflecting this dosing titration is available.
Maintenance Dosing (week 2-12): 1mg twice daily
Orally food has no effect on pharmacokinetics. Varenicline should be taken after eating and with a full
glass of water to reduce nausea. Patients who cannot tolerate adverse events may require temporary reduction in dose.
If patient successfully quits smoking during the 12 weeks, may continue for another 12 weeks to help
maintain success. If not successful in first 12 weeks, then stop medication and reassess factors
contributing to failure.
The website is relevant not only to those concerned with tobacco control but also, more generally, to those who wish to teach, study or
www.deathsfromsmoking.net. See this web site for information on the hazards of smoking and the
benefits from stopping. One in five American adults, or nearly 45 million people smoke cigarettes, which
kills nearly 512,000 American men and women a year. About 192,000 die in middle age from smoking.
Tobacco use, particularly cigarette smoking, is the single most preventable cause of death in the U.S. and
is responsible for a growing list of cancers, as well as chronic diseases, including those of the lung and
heart. About one in three of all cancer deaths is due to smoking.
Prepared for Upper Peninsula Pharmacy and Therapeutics Committee October 11, 2006 meeting.
Korunda Pain Management Center The following questions are designed to help your physical understand your current pain patterns and past treatment history. If you do not understand any of the following questions, please ask for assistant. Name: ___________________________________ Age: _________ DOB: _____________ Referring Physician: ________________________________________ Primary care Ph
LISTA LUCRARILOR PUBLICATE IN REVISTE CU FACTOR DE IMPACT (ISI) DE CATRE CADRELE DIDACTICE DIN UVT IN ANUL 2009 Nr. Autori lucrare Titlul lucrarii Revista in care a aparut Volum (fascicula) pagini Some mechanisms concerning the electrical conductivity of Journal of Industrial and Engineering Chemistry magnetorheological suspensions in magnetic field. 2 Anitas, M., Balasoiu, M.,